ERBB2 and breast carcinoma: Table 2 [63,64,65,66,67,68,69,70,71] summarizes the main characteristics and findings from principal clinical trials that have investigated anti-HER2 monoclonal antibodies (mABs), ICIs, and PARPis as first-line therapies in advanced breast cancer.